Page last updated: 2024-08-24

2,3-trimethylene-4-quinazolone and Lung Neoplasms

2,3-trimethylene-4-quinazolone has been researched along with Lung Neoplasms in 1 studies

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's1 (100.00)2.80

Authors

AuthorsStudies
Chatterjee, E; Dhingra, A; Grewal, AS; Guru, SK; Lee, SB; Liou, JP; Mathew, J; Nepali, K; Pan, CH; Rao, NV; Sharma, R; Sharma, S1

Other Studies

1 other study(ies) available for 2,3-trimethylene-4-quinazolone and Lung Neoplasms

ArticleYear
Accommodation of ring C expanded deoxyvasicinone in the HDAC inhibitory pharmacophore culminates into a tractable anti-lung cancer agent and pH-responsive nanocarrier.
    European journal of medicinal chemistry, 2022, Oct-05, Volume: 240

    Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Histone Deacetylase Inhibitors; Hydrogen-Ion Concentration; Lung Neoplasms; Mice; Nanoparticle Drug Delivery System; Quinazolines; Quinazolinones

2022